---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-266078"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-06-10T21:22:21+00:00"
generated_at: "2026-06-10T21:24:21.156185+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics raises ~$566.5M in public offering to fund R&D and commercialization

## Summary
- Offering of 18,166,667 shares at $30.00/share and pre-funded warrants for 1,833,395 shares at $29.999/warrant.
- Net proceeds expected ~$566.5M after underwriting discounts and expenses; closing expected June 11, 2026.
- Proceeds for R&D, pivotal trial, potential commercialization, G&A, and capex; cash runway extended into 2030.
- Underwriters granted 30-day option to purchase up to 3,000,009 additional shares at public offering price.

## SEC filing metadata
- accession: 0001193125-26-266078
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-06-10T21:22:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526266078/0001193125-26-266078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526266078/d81492d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-266078
- JSON: https://secwatch.observer/filing/0001193125-26-266078.json
- Plain text: https://secwatch.observer/filing/0001193125-26-266078.txt

## Key facts
- Material Agreements
  Tango Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives (effective 2026-06-09).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC and Leerink Partners LLC as representatives
  - Effective: 2026-06-09
  source text: On June 9, 2026, Tango Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives (the “Representatives”) to the several underwriters named in the Underwriting Agreement (collectively, the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 18,166,667 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,833,395 shares of Common Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312526266078/0001193125-26-266078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.